{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B%3A+Treatment+E&page=2",
    "query": {
      "intervention": "Part B: Treatment E",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 135,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B%3A+Treatment+E&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B%3A+Treatment+E&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T22:58:29.146Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04058132",
      "title": "Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Sildenafil Citrate 50Mg Tab",
          "type": "DRUG"
        },
        {
          "name": "functional Near-infrared Spectroscopy (fNIRS)",
          "type": "DEVICE"
        },
        {
          "name": "Carbon Dioxide (CO2) 5%",
          "type": "OTHER"
        },
        {
          "name": "Neuropsychological Assessments",
          "type": "OTHER"
        },
        {
          "name": "Gadolinium contrast infusion",
          "type": "DRUG"
        },
        {
          "name": "Blood sample collection for research purposes",
          "type": "PROCEDURE"
        },
        {
          "name": "Structural brain Magnetic Resonance Imaging (MRI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Uniformed Services University of the Health Sciences",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-08-09",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04058132"
    },
    {
      "nct_id": "NCT06533280",
      "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Part A, C and D: VH3739937 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A: VH3739937 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A and C: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment E",
          "type": "DRUG"
        },
        {
          "name": "Part D: Probe cocktail",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-02",
      "completion_date": "2024-08-14",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533280"
    },
    {
      "nct_id": "NCT01627587",
      "title": "A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obstetric Labour, Premature"
      ],
      "interventions": [
        {
          "name": "GSK221149 750 mg",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "GSK221149 100 mg",
          "type": "DRUG"
        },
        {
          "name": "GSK221149 750 mg Fasted",
          "type": "DRUG"
        },
        {
          "name": "GSK221149 750 mg + Food",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 46,
      "start_date": "2011-12-12",
      "completion_date": "2012-02-09",
      "has_results": false,
      "last_update_posted_date": "2017-06-15",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627587"
    },
    {
      "nct_id": "NCT03846843",
      "title": "OCR002-SP103 - Oral Immediate Release Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cirrhosis"
      ],
      "interventions": [
        {
          "name": "OCR-002 IR Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "OCR-002 Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "OCR-002 IV Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-08-15",
      "completion_date": "2017-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 1,
      "location_summary": "Coronado, California",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03846843"
    },
    {
      "nct_id": "NCT02833831",
      "title": "Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ALS-008176",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 103,
      "start_date": "2016-06-02",
      "completion_date": "2017-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833831"
    },
    {
      "nct_id": "NCT03933488",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "TAK-994",
          "type": "DRUG"
        },
        {
          "name": "TAK-994 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2019-05-01",
      "completion_date": "2020-03-29",
      "has_results": false,
      "last_update_posted_date": "2020-06-24",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03933488"
    },
    {
      "nct_id": "NCT04223349",
      "title": "A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-70033093",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 66,
      "start_date": "2020-01-10",
      "completion_date": "2020-04-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04223349"
    },
    {
      "nct_id": "NCT02345707",
      "title": "Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Cabotegravir 30 mg current formulation",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 30 mg micronized new formulation 500 M",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 30 mg unmicronized new formulation 500 U",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 30 mg micronized new formulation 650 M",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 30 mg unmicronized new formulation 650 U",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2015-03",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-07-13",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345707"
    },
    {
      "nct_id": "NCT03468426",
      "title": "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-squamous, Non-Small-Cell Lung Cancer",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BI 836880",
          "type": "DRUG"
        },
        {
          "name": "Ezabenlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2018-07-05",
      "completion_date": "2024-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468426"
    },
    {
      "nct_id": "NCT04133636",
      "title": "A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "JNJ-68284528",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2019-11-07",
      "completion_date": "2028-08-25",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-02T22:58:29.146Z",
      "location_count": 33,
      "location_summary": "San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04133636"
    }
  ]
}